secwatch / observer
8-K filed February 6, 2025, 6:59 PM ET CIK 0001811623
leadership confidence high sentiment negative materiality 0.70

PaxMedica CFO/COO Stephen Sheldon resigns; director Zachary Rome also quits board

PaxMedica, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Zachary Rome

Director
PaxMedica, Inc.
Effective
2025-01-31
Filed
February 6, 2025, 6:59 PM ET
On January 31, 2025, Zachary Rome resigned from the Board for personal reasons, effective immediately.
Departed

Stephen D. Sheldon

Chief Financial Officer and Chief Operational Officer
PaxMedica, Inc.
Effective
2025-01-31
Filed
February 6, 2025, 6:59 PM ET
On January 31, 2025, Stephen D. Sheldon, chief financial officer and chief operational officer of PaxMedica, Inc., a Delaware corporation (the “Company”), provided notice of his resignation as an executive officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Zachary Rome resigned as Director at PaxMedica, Inc..

Action
resigned
Role
Director
Exact text from the filing
On January 31, 2025, Zachary Rome resigned from the Board for personal reasons, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen D. Sheldon resigned as Chief Financial Officer and Chief Operational Officer at PaxMedica, Inc..

Action
resigned
Role
Chief Financial Officer and Chief Operational Officer
Exact text from the filing
On January 31, 2025, Stephen D. Sheldon, chief financial officer and chief operational officer of PaxMedica, Inc., a Delaware corporation (the “Company”), provided notice of his resignation as an executive officer of the Company, effective immediately.
View on SEC.gov
Source: SEC EDGAR
accession 0001493152-25-005181
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.